MedTrace Logo

Use of Misoprostol in Hysteroscopic Myomectomy

NCT06049745 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-09-22

No results posted yet for this study

Summary

Hysteroscopic myomectomy is typically suitable for myomas measuring under 4 cm in size. The utilization of misoprostol before the procedure can facilitate uterine access, decrease fluid absorption, and reduce blood loss, consequently leading to a decrease in the overall procedure time. In this randomized trial, the investigators aim to investigate the impact of misoprostol administration and its effects on each of the mentioned parameters.

Conditions

  • Hysteroscopic Myomectomy

Interventions

DRUG

Misoprostol 400 Microgram Oral Tablet

S.L misoprostol 400 mcg

Sponsors & Collaborators

  • Assuta Medical Center

    collaborator OTHER

  • Assuta Ashdod Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2026-08-31
Completion
2026-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06049745 on ClinicalTrials.gov